These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21982545)

  • 1. Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.
    Jarosławski S; Toumi M
    BMC Health Serv Res; 2011 Oct; 11():259. PubMed ID: 21982545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
    Dunlop WCN; Staufer A; Levy P; Edwards GJ
    Health Policy; 2018 May; 122(5):528-532. PubMed ID: 29567205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of Surrogate and Patient-Relevant Endpoints in Outcomes-Based Market Access Agreements : Current Debate.
    Toumi M; Jarosławski S; Sawada T; Kornfeld Å
    Appl Health Econ Health Policy; 2017 Feb; 15(1):5-11. PubMed ID: 27581118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.
    Morgan SG; Vogler S; Wagner AK
    Health Policy; 2017 Apr; 121(4):354-362. PubMed ID: 28238340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pricing in the Market for Anticancer Drugs.
    Howard DH; Bach PB; Berndt ER; Conti RM
    J Econ Perspect; 2015; 29(1):139-62. PubMed ID: 28441702
    [No Abstract]   [Full Text] [Related]  

  • 8. [Innovative medicines and market access agreements].
    Toumi M; Zard J; Duvillard R; Jommi C
    Ann Pharm Fr; 2013 Sep; 71(5):302-25. PubMed ID: 24075701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence.
    Jarosławski S; Toumi M
    Appl Health Econ Health Policy; 2011 Jul; 9(4):209-15. PubMed ID: 21682349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
    Maskineh C; Nasser SC
    Value Health Reg Issues; 2018 Sep; 16():33-38. PubMed ID: 29936067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value-based differential pricing: efficient prices for drugs in a global context.
    Danzon P; Towse A; Mestre-Ferrandiz J
    Health Econ; 2015 Mar; 24(3):294-301. PubMed ID: 24327269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Funding breakthrough therapies: A systematic review and recommendation.
    Hanna E; Toumi M; Dussart C; Borissov B; Dabbous O; Badora K; Auquier P
    Health Policy; 2018 Mar; 122(3):217-229. PubMed ID: 29223847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of aligning the implementation of new payment models for innovative pharmaceuticals in European countries.
    Kaló Z; Niewada M; Bereczky T; Goettsch W; Vreman RA; Xoxi E; Trusheim M; Callenbach MHE; Nagy L; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):181-187. PubMed ID: 37970637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk sharing in managed entry agreements-A review of the Swedish experience.
    Andersson E; Svensson J; Persson U; Lindgren P
    Health Policy; 2020 Apr; 124(4):404-410. PubMed ID: 32093981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact Reimbursement Act on the pharmaceutical market in Poland].
    Giermaziak W
    Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries.
    Rotar AM; Preda A; Löblová O; Benkovic V; Zawodnik S; Gulacsi L; Niewada M; Boncz I; Petrova G; Dimitrova M; Klazinga N
    Health Policy; 2018 Mar; 122(3):230-236. PubMed ID: 29373186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.